Biobeat Technologies, Ltd. has created a disposable, patch-based ambulatory blood pressure monitoring (ABPM) system that collects continuous, 24-hour blood-pressure data without the discomfort of traditional cuff inflation cycles. The sensor allows patients to conduct normal daily activities and sleep undisturbed, after which a high-quality report is automatically uploaded to the institution’s electronic medical records. With operations in Tel Aviv and Boca Raton, the company is focused on making ABPM a standard of care for more than 100 million hypertensive patients in the United States. Biobeat’s solution is already FDA-cleared and positioned to replace cumbersome cuff-based devices that suffer from poor patient compliance. The firm plans to use its newly raised capital to build a field sales team and accelerate U.S. commercialization. Financially, Biobeat just secured a $50 million Series B round, adding to its resources for market expansion and product roll-out.

Total raised

$50M

Funding rounds

1

Latest round

Series B

Latest activity

Dec 2025